A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
← catalyst calendarSponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
26actual
Sites
20
Countries
China, Japan, North Macedonia +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-07 | actual | When the study began enrolling |
| Primary completion | 2025-04-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-01 | actual | The whole study's end, after follow-up |
| First posted | 2022-12-06 | actual | When this record first appeared on the registry |
| Results posted | 2026-05-28 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-05-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Lupus Erythematosus
Interventions
- Drug: DS-7011a
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus Erythematosus
measured Post first dose up to Week 24
Posted documents
hosted by the registry — we link, never re-serveStudy Protocol and Statistical Analysis Planposted 2024-04-12 · 2.4 MB · Prot_SAP_000.pdf
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed